For the quarter ending 2026-03-31, LSTA had -$2,896K decrease in cash & cash equivalents over the period. -$3,083K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -4,489 | -2,954 | -4,249 | -9,383 |
| Loss from equity method investment | - | 0 | 0 | 0 |
| Share-based compensation | 364 | 225 | 232 | 769 |
| Impairment of non-financial asset | - | 127 | - | - |
| Depreciation and amortization | 2 | 15 | 44 | 87 |
| Amortization/accretion on marketable securities | 0 | 0 | 14 | 61 |
| Allowance for credit losses | - | 500 | - | - |
| Accounts receivable | 0 | -3 | 1 | -399 |
| Prepaid and other current assets | -807 | -335 | -344 | -63 |
| Other assets | 0 | 0 | -50 | -90 |
| Accounts payable, accrued liabilities and other liabilities | 233 | -1,500 | 252 | -1,322 |
| Net cash used in operating activities | -3,083 | -3,249 | -3,342 | -9,358 |
| Purchase of marketable securities | 0 | 0 | 0 | 9,180 |
| Sale of marketable securities | 0 | 0 | 5,150 | 19,144 |
| Investment in impilo therapeutics | - | 0 | - | - |
| Purchase of property and equipment | 0 | 0 | 0 | 28 |
| Investment in impilo therapeutics | - | - | 0 | 0 |
| Net cash provided by investing activities | 0 | 0 | 5,150 | 9,936 |
| Proceeds from exercise of options | 124 | 0 | 0 | 8 |
| Tax withholding payments on net share settlement equity awards | 159 | 0 | 0 | 253 |
| Proceeds from exercise of warrants | 216 | - | - | - |
| Net proceeds from issuance of common stock | 0 | 205 | 353 | 286 |
| Net cash provided by (used in) financing activities | 181 | 205 | 353 | 41 |
| Effect of exchange rate changes on cash | 6 | 2 | 2 | 7 |
| Net (decrease) increase in cash and cash equivalents | -2,896 | -3,042 | 2,163 | 626 |
| Cash and cash equivalents at beginning of period | 15,956 | 18,998 | 16,209 | - |
| Cash and cash equivalents at end of period | 13,060 | 15,956 | 18,998 | - |
LISATA THERAPEUTICS, INC. (LSTA)
LISATA THERAPEUTICS, INC. (LSTA)